You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Pravastatin lowered coronary disease risk in elderly persons with or at risk of vascular disease

https://doi.org/10.1136/ebm.8.4.107

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2002) Lancet 360, 1623. Shepherd J, Blauw GJ, Murphy MB, et al.. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.. ;. :. –30.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: In elderly persons with or at risk of vascular disease, what is the effectiveness and safety of pravastatin?

    Design

    Randomised (allocation concealed*), blinded (clinicians, participants, data collectors, and outcome assessors),* placebo controlled trial with mean follow up of 3.2 years (Prospective Study of Pravastatin in the Elderly at Risk [PROSPER]).

    Setting

    Scotland, Ireland, and the Netherlands.

    Participants

    5804 participants between 70–82 years (mean age 75 y, 52% women) who had a history of vascular disease (coronary, cerebral, or peripheral) or risk factors for vascular disease (eg, smoking, hypertension, or diabetes), a total plasma cholesterol concentration between 4.0 and 9.0 mmol/l, and a triglyceride concentration <6.0 mmol/l. Participants with poor cognitive function (Mini-Mental State Examination score <24) were excluded. Follow up …

    View Full Text

    Footnotes

    • Source of funding: Bristol-Myers Squibb.

    • For correspondence: Professor J Shepherd, Royal Infirmary, Glasgow, UK.jshepherd{at}gri-biochem.org.uk

    • Abstract and commentary also appear in ACP Journal Club.

    • ↵* See glossary.